HALO logo
halo search icon
Autolus Therapeutics Plc Sponsored ADR
Autolus Therapeutics Plc Sponsored ADR
AUTL · NAS

Autolus Therapeutics Plc Sponsored ADR

US$1.62

Price Arrow-0.01 (-0.613%)
20/05/2026 04:00:00 PM
All-ConsensusBig CandleRecent Earnings upgrade
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Autolus Therapeutics Plc Sponsored ADR Overview

AUTL Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About AUTL

icon

Telephone

44.20.3829.6230

icon

Address

White City, 191 Wood Lane, The Mediaworks, London, Greater London W12 7FP

Description

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

AUTL Price Chart

Key Stats

Market Cap

US$433.83M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 1.17 - 2.7

Trade Value (12mth)

US$1,050,286.00

1 week

0%

1 month

5.16%

YTD

-12.83%

1 year

10.88%

All time high

53.24

Key Fundamentals

EPS 3 yr Growth

-30.80%

EBITDA Margin

-359.40%

Operating Cashflow

-$284m

Free Cash Flow Return

-46.00%

ROIC

-46.60%

Interest Coverage

-7.40

Quick Ratio

5.40

Other Data

Shares Outstanding (Fully Diluted)

266m

HALO Sector

Healthcare

Next Company Report Date

10-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

AUTL Announcements

Latest Announcements

DateAnnouncements
15 May 26
14 May 26
14 May 26
14 May 26
30 April 26

AUTL Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-1.2-0.87-1.08locklocklock
EPS (Fully Diluted)
$locklocklocklock-1.2-0.87-1.08locklocklock
Growth
%locklocklocklock23.228.1-25.2locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS)?
Halo FAQ
The current share price of Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) is USD$1.62.
What is the 52-week high share price for Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS)?
Halo FAQ
The 52-week high share price for Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) is USD$2.70.
What is the 52-week low share price for Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS)?
Halo FAQ
The 52-week low share price for Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) is USD$1.17.
What is the dividend yield for Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS)?
Halo FAQ
Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) does not pay a dividend.
What was Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) last dividend payment?
Halo FAQ
Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) does not pay a dividend.
What is the franking level for Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS)?
Halo FAQ
Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) has a franking level of 0.00%.
In which sector is Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) classified?
Halo FAQ
Autolus Therapeutics Plc Sponsored ADR (AUTL:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.